Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy
Rui Han,Xiwu Rao,Huiling Zhou,Lingeng Lu
DOI: https://doi.org/10.2147/ijn.s461289
IF: 7.033
2024-05-28
International Journal of Nanomedicine
Abstract:Rui Han, 1, 2 Xiwu Rao, 3 Huiling Zhou, 4 Lingeng Lu 5– 7 1 Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, People's Republic of China; 2 Department of Chinese Medicine, Naval Medical University, Shanghai, People's Republic of China; 3 Department of Oncology, The First Hospital Affiliated to Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China; 4 Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, People's Republic of China; 5 Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT, USA; 6 School of Medicine, Center for Biomedical Data Science, Yale University, New Haven, CT, USA; 7 Yale Cancer Center, Yale University, New Haven, CT, USA Correspondence: Rui Han, Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, People's Republic of China, Email The utilization of PD-1/PD-L1 inhibitors marks a significant advancement in cancer therapy. However, the efficacy of monotherapy is still disappointing in a substantial subset of patients, necessitating the exploration of combinational strategies. Emerging from the promising results of the KEYNOTE-942 trial, RNA-based therapies, particularly circRNAs and piRNAs, have distinguished themselves as innovative sensitizers to immune checkpoint inhibitors (ICIs). These non-coding RNAs, notable for their stability and specificity, were once underrecognized but are now known for their crucial roles in regulating PD-L1 expression and bolstering anti-cancer immunity. Our manuscript offers a comprehensive analysis of selected circRNAs and piRNAs, elucidating their immunomodulatory effects and mechanisms, thus underscoring their potential as ICIs enhancers. In conjunction with the recent Nobel Prize-awarded advancements in mRNA vaccine technology, our review highlights the transformative implications of these findings for cancer treatment. We also discuss the prospects of circRNAs and piRNAs in future therapeutic applications and research. This study pioneers the synergistic application of circRNAs and piRNAs as novel sensitizers to augment PD-1/PD-L1 inhibition therapy, demonstrating their unique roles in regulating PD-L1 expression and modulating immune responses. Our findings offer a groundbreaking approach for enhancing the efficacy of cancer immunotherapy, opening new avenues for treatment strategies. This abstract aims to encapsulate the essence of our research and the burgeoning role of these non-coding RNAs in enhancing PD-1/PD-L1 inhibition therapy, encouraging further investigation into this promising field. Keywords: CircRNA, piwi-RNA, immunotherapy, PD-1/PD-L1 blockade, immunotherapy sensitizer, combination therapy According to GLOBOCAN, there were 19.3 million. 1 , new cancer cases and 10.0 million cancer-related deaths worldwide in 2020. 2 In 2019, the World Health Organization (WHO) estimated that cancer ranks as the primary or secondary cause of death before the age of 70 in 112 out of 183 countries. 2 As a formidable ailment, the available therapeutic options for cancer remain limited. 3 The advent of immune checkpoint inhibitor therapy, including PD-1 (Programmed Cell Death Protein 1) and PD-L1 (Programmed Death-Ligand 1) inhibitors, has revolutionized cancer treatment and, to some extent, improved clinical outcomes for cancer patients. However, a significant portion of cancer patients still struggle to achieve sustained and optimal clinical benefits. 3–5 Therefore, the concept of incorporating a sensitizer into PD-1/PD-L1 inhibitor-based therapy has been developed to enhance clinical benefits for cancer patients. 6 Existing or potential sensitizers, such as tyrosine kinase inhibitors, carbonic anhydrase XII inhibitors, histone deacetylase 2 inhibitors, and RNA therapy, have expanded the range of options and possibilities for combating malignancies. 6–9 The awarding of the 2023 Nobel Prize for the pioneering application of mRNA vaccines in combating COVID-19 has underscored the potential of gene therapy to modulate the immune response, bringing it widespread recognition. Furthermore, the safety of such therapies has gained acceptance, heightening the imperative to leverage gene therapy in cancer treatment, especially considering its proven ability to regulate immune system functions. 10 Moreover, recent findings have provided initial evidence supporting the practicality of utilizing Immune Checkpoint Inhibitors (ICIs) in conjunction with non-coding RNA (ncRNA) for cancer treatment. 11,12 -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology